Organigram launches $561-million takeover offer for Aurora Cannabis
Organigram (OGI) has offered to acquire Aurora Cannabis (ACB) for $561 million, or $7.80 per share, a 21% premium over Curaleaf's (CURLF) offer. Aurora, once valued at $14 billion, has struggled with overpaying for acquisitions and declining market value. The deal requires approval from at least two-thirds of Aurora shareholders.
How this was made
The 30-second read
Why it matters
The transaction creates immediate pricing catalysts for both companies while raising questions about financing, integration, and regulatory clearance.
Market read
The deal is a material M&A event in the cannabis sector, likely moving both stocks and influencing peer valuations.
What to watch
Regulatory approvals in the EU and potential antitrust scrutiny could delay or derail the transaction.
Background
Organigram, a Canadian cannabis producer, is pursuing a white‑knight acquisition of Aurora Cannabis, which has struggled after a series of costly acquisitions and impairments.
Market effects
Consolidation in the Canadian cannabis sector may lift peers as the market reassesses valuations.
Canadian cannabis stocks could see heightened volatility as investors evaluate merger outcomes.
The deal highlights growing interest in international cannabis markets, potentially influencing global commodity sentiment.
Counterpoint
The premium may be insufficient given Aurora's distressed balance sheet, suggesting the deal could be renegotiated or fail.
Key entities
- CompanyOrganigram Global Inc.
Acquirer offering $561 million for Aurora.
- CompanyAurora Cannabis Inc.
Target of the takeover, currently undervalued.
- InvestorBritish American Tobacco
Provides $188 million private placement financing.
